69.89

3.14% 2.13

Handel nachbörslich: 69.89

Edwards Lifesciences Corp (EW)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EW? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$67.76

Offen:

$67.63

24-Stunden-Volumen:

6.96M

Relative Volume:

1.19

Marktkapitalisierung:

$40.52B

Einnahmen:

$6.60B

Nettoeinkommen (Verlust:

$4.16B

KGV:

29.87

EPS:

2.34

Netto-Cashflow:

$490.10M

1W Leistung:

+4.78%

1M Leistung:

-0.54%

6M Leistung:

-21.60%

1J Leistung:

+4.47%

1-Tages-Spanne:

$67.58

$71.08

1-Wochen-Bereich:

$64.89

$71.08

52-Wochen-Spanne:

$58.93

$96.12

Edwards Lifesciences Corp Stock (EW) Company Profile

Firmenname

Edwards Lifesciences Corp

Sektor

Healthcare (1196)

Branche

Medical Devices (153)

Telefon

(949) 250-2500

Adresse

ONE EDWARDS WAY, IRVINE, CA

Mitarbeiter

19,800

Twitter

@edwardslifesci

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

EW's Discussions on Twitter

Vergleichen Sie EW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EW	69.89	40.52B	6.60B	4.16B	490.10M	2.34
ABT	117.36	202.64B	41.22B	5.77B	6.49B	2.94
SYK	389.40	150.72B	21.97B	3.59B	3.21B	6.74
BSX	90.45	133.82B	15.91B	1.79B	1.89B	0.82
MDT	87.59	112.98B	32.58B	3.93B	5.15B	2.71

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-09-18	Herabstufung	Jefferies	Buy → Hold
2024-07-31	Hochstufung	Daiwa Securities	Neutral → Outperform
2024-07-29	Hochstufung	Wolfe Research	Underperform → Peer Perform
2024-07-25	Herabstufung	BofA Securities	Buy → Neutral
2024-07-25	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-25	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-07-25	Herabstufung	TD Cowen	Buy → Hold
2024-07-25	Herabstufung	Truist	Buy → Hold
2024-05-30	Eingeleitet	Goldman	Buy
2024-05-22	Hochstufung	Citigroup	Neutral → Buy
2024-05-14	Hochstufung	Deutsche Bank	Hold → Buy
2024-03-07	Hochstufung	BofA Securities	Neutral → Buy
2024-02-02	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-01-04	Herabstufung	Evercore ISI	Outperform → In-line
2023-12-11	Herabstufung	Citigroup	Buy → Neutral
2023-11-28	Herabstufung	Wolfe Research	Peer Perform → Underperform
2023-09-26	Hochstufung	Oppenheimer	Perform → Outperform
2023-07-19	Eingeleitet	Robert W. Baird	Outperform
2023-05-30	Fortgesetzt	Morgan Stanley	Overweight
2023-03-29	Eingeleitet	UBS	Neutral
2023-03-08	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-02-06	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-01-31	Herabstufung	Bernstein	Outperform → Underperform
2023-01-30	Herabstufung	Piper Sandler	Overweight → Neutral
2022-12-06	Herabstufung	Stifel	Buy → Hold
2022-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2022-10-26	Eingeleitet	Mizuho	Buy
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Buy
2022-07-29	Herabstufung	Canaccord Genuity	Buy → Hold
2022-04-13	Eingeleitet	Truist	Buy
2022-04-06	Eingeleitet	Wolfe Research	Outperform
2022-03-16	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-27	Bestätigt	Citigroup	Buy
2022-01-27	Bestätigt	Evercore ISI	Outperform
2022-01-27	Bestätigt	Raymond James	Outperform
2022-01-27	Bestätigt	Stifel	Buy
2022-01-27	Bestätigt	UBS	Neutral
2021-12-17	Hochstufung	JP Morgan	Neutral → Overweight
2021-12-15	Hochstufung	Citigroup	Neutral → Buy
2021-12-10	Eingeleitet	RBC Capital Mkts	Outperform
2021-12-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2021-07-30	Bestätigt	Canaccord Genuity	Buy
2021-07-30	Bestätigt	Deutsche Bank	Hold
2021-07-30	Bestätigt	Jefferies	Buy
2021-07-30	Bestätigt	Morgan Stanley	Overweight
2021-07-30	Bestätigt	Oppenheimer	Outperform
2021-07-30	Bestätigt	Stifel	Buy
2021-07-30	Bestätigt	UBS	Neutral
2021-07-30	Bestätigt	Wells Fargo	Equal Weight
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-15	Eingeleitet	Atlantic Equities	Neutral
2021-04-05	Hochstufung	Evercore ISI	In-line → Outperform
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-12-11	Bestätigt	Canaccord Genuity	Buy
2020-09-11	Eingeleitet	Wolfe Research	Underperform
2020-04-28	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-13	Eingeleitet	Goldman	Neutral
2020-02-06	Fortgesetzt	BTIG Research	Neutral
2020-01-10	Eingeleitet	Oppenheimer	Outperform
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-10-24	Bestätigt	Canaccord Genuity	Buy
2019-09-23	Eingeleitet	Piper Jaffray	Overweight
2019-07-24	Bestätigt	BofA/Merrill	Buy
2019-03-18	Bestätigt	Canaccord Genuity	Buy
2019-01-18	Hochstufung	BofA/Merrill	Neutral → Buy
2019-01-03	Eingeleitet	Deutsche Bank	Hold
2018-11-28	Eingeleitet	UBS	Neutral
2018-10-16	Eingeleitet	Barclays	Underweight
2018-10-02	Herabstufung	BofA/Merrill	Buy → Neutral
2018-10-02	Herabstufung	Guggenheim	Buy → Neutral

Alle ansehen

Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten

12:02 PM

Edwards Lifesciences Corporation Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationEW - Marketscreener.com

12:02 PM

09:13 AM

Edwards Lifesciences wins Meril injunction as pro-patentee decisions continue to flow from UPC - IAM

09:13 AM

08:35 AM

Edwards deals a severe blow to Meril with regular advisors - JUVE Patent

08:35 AM

Nov 17, 2024

Kessler Topaz Meltzer & Check, LLP Notifies Edwards Lifesciences Corporation Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit - GlobeNewswire Inc.

Nov 17, 2024

S&CO Inc. Has $4.06 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat

Nov 17, 2024

2024-11-17 | DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation | NYSE:EW | Press Release - Stockhouse Publishing

Nov 17, 2024

Nov 16, 2024

Edwards Lifesciences quarterly net falls on charge - Reuters.com

Nov 16, 2024

Ipswich Investment Management Co. Inc. Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Edwards Lifesciences Corp Class Action: Lead Plaintiff Deadline is 12/13/24; Contact Robbins LLP for Information - Benzinga

Nov 15, 2024

Edwards Lifesciences Corp Class Action: Lead Plaintiff Deadline is 12/13/24; Contact Robbins LLP for - EIN News

Nov 15, 2024

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Nov 15, 2024

EW COURT REPORT: A Class Action has been Filed Against Edwards Lifesciences, Investors are Urged to Contact BFA Law by December 13 Deadline - Newsfile

Nov 15, 2024

Edwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion Of Market CapitalizationHagens Berman - Marketscreener.com

Nov 15, 2024

Huntington National Bank Lowers Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat

Nov 15, 2024

KBC Group NV Buys 104,499 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat

Nov 15, 2024

Finansavisen - Finansavisen

Nov 15, 2024

Nov 14, 2024

EW Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Edwards Lifesciences Corporation Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - Markets Insider

Nov 14, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation - Marketscreener.com

Nov 14, 2024